The Oral NK 1 Antagonist Aprepitant for Prevention of Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy

By Ronald de Wit  

American Journal of Cancer, Vol. 4, Iss. 1, 2005-01 ,pp. : 35-48

Adis International

Access to resources Recommend Favorite

The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer

By              

International Journal of Oncology, Vol. 45, Iss. 4, 2014-01 ,pp. : 1658-1672

Spandidos Publications

Access to resources Recommend Favorite

Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamide

By Hesketh Paul   Younger Jerry   Sanz-Altamira Pedro   Hayden Melissa   Bushey Julie   Trainor Brian   Krentzin Michael   Nowd Peter   Arnaoutakis Konstantinos   Hesketh Ann  

Supportive Care in Cancer, Vol. 17, Iss. 8, 2009-08 ,pp. : 1065-1070

Springer Publishing Company

Access to resources Recommend Favorite

Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients

By Loos Walter   Wit Ronald   Freedman Steven   Dyck Kristien   Gambale Jay   Li Susie   Murphy Gail   Noort Connie   Bruijn Peter   Verweij Jaap  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 3, 2007-03 ,pp. : 407-412

Springer Publishing Company

Access to resources Recommend Favorite

Effectiveness of Serotonin-Receptor Antagonist Antiemetic Therapy over Successive Courses of Carboplatin-Based Chemotherapy

By Markman M.R.   Peterson G.   Kulp B.   Markman M.  

Gynecologic Oncology, Vol. 85, Iss. 3, 2002-06 ,pp. : 435-437

Academic Press

Access to resources Recommend Favorite